Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
The alpha-synuclein propagation and seeding biomarker track at MDS 2026 represents one of the most actively evolving areas in Parkinson's disease (PD) research. With seed amplification assays (SAA) transitioning from research tools to clinically validated diagnostics, and propagation mechanisms increasingly well-characterized, this year's sessions are expected to showcase significant advances in biomarker-driven patient management and therapeutic development[@pezzullo2024].
This page provides comprehensive coverage of:
- Seed amplification assay clinical validation and kinetic analysis
- Propagation mechanisms and cellular uptake pathways
- Prodromal PD detection and disease staging
- Peripheral biomarker development (skin, blood)
- Alpha-synuclein PET imaging advances
- Therapeutic implications for disease modification
Alpha-synuclein seed amplification assays (αSyn-SAA) detect pathological, aggregated alpha-synuclein using the inherent prion-like property of pathogenic species to template the conversion of recombinant substrate[@pezzullo2024]. The two primary formats:
RT-QuIC exploits cyclic shaking to accelerate seeded aggregation:
- Principle: Pathological seeds catalyze the conversion of normal α-syn monomers into amyloid fibrils
- Detection: Thioflavin T fluorescence monitors amyloid formation in real-time
- Sensitivity: 85-95% for Parkinson's disease CSF
- Specificity: 90-98% in healthy controls
PMCA uses sonication instead of shaking:
- Principle: Sonication fragments fibrils, creating new seed ends that accelerate conversion
- Sample types: CSF, tissue samples, peripheral tissues
- Performance: Comparable to RT-QuIC
Advanced kinetic analysis provides diagnostic and prognostic information beyond simple binary results[@orru2025]:
| Kinetic Parameter |
Clinical Interpretation |
| Lag time |
Time to detectable aggregation - correlates inversely with seed concentration |
| Maximum fluorescence (Fmax) |
Reflects total fibril mass produced |
| Slope (Vmax) |
Aggregation rate - may predict disease progression rate |
| Area under curve (AUC) |
Integrated measure of seeding activity |
Expected highlights from clinical validation studies:
- Large-scale prospective studies: Multi-center validation cohorts (n > 2000)
- Longitudinal tracking: SAA kinetics predict progression[@siddiqi2024]
- ** standardization efforts**: International consensus protocols
- Regulatory status: FDA Breakthrough Device designation progress
REM sleep behavior disorder (RBD) represents the strongest prodromal marker for synucleinopathies[@iranzoweinberg2025]:
- Conversion rate: ~80-90% of individuals with idiopathic RBD eventually develop a synucleinopathy
- Seeding positivity: αSyn-SAA positive in 85-95% of idiopathic RBD cases
- Lead time: Seeding detectable up to 10-15 years before clinical PD diagnosis
| Stage |
Clinical Status |
SAA Result |
Seed Concentration |
| Preclinical |
Asymptomatic genetic risk |
Variable |
Low |
| Prodromal |
RBD, hyposmia, autonomic |
Positive |
Moderate |
| Early PD |
Motor symptoms < 2 years |
Positive |
High |
| Established PD |
Motor symptoms > 2 years |
Positive |
Highest |
| Advanced PD |
Dementia, falls |
Positive |
Variable |
Key developments in prodromal detection:
- Population screening: Feasibility of SAA-based screening in at-risk populations
- Genetic stratification: Combining genetic risk scores with SAA
- Multiplex panels: Simultaneous detection of α-syn, tau, β-amyloid seeds
Alpha-synuclein exhibits prion-like properties, spreading between neurons and propagating pathology throughout the nervous system[@valera2023]. Key mechanisms:
| Pathway |
Description |
Therapeutic Target |
| Exocytosis |
Activity-dependent release via synaptic vesicles |
Reduce neuronal hyperexcitability |
| Exosomes |
Extracellular vesicles containing pathological species |
Block exosome release |
| Direct membrane translocation |
Pore-like formation |
Stabilize membranes |
| Lysosomal exocytosis |
Release following lysosomal permeabilization |
Restore lysosomal function |
Neurons and glia take up extracellular alpha-synuclein through:
- Receptor-mediated endocytosis: LRP1, LRP2 (megalin), MHC-I, TLR2
- Clathrin-dependent pathways: Bulk endocytic uptake
- Direct membrane penetration: Oligomeric species
- Synaptic vesicle-mediated uptake: Endocytosis at synapses
Distinct "strains" - conformational variants - exhibit different biological properties[7]:
- PD strains: Characteristic robust seeding in CSF
- MSA strains: Different conformational properties, lower detection rates
- DLB strains: Intermediate patterns between PD and MSA
Strain-specific therapies represent a future precision medicine approach.
| Factor |
Effect on Propagation |
Therapeutic Implication |
| SNCA multiplication |
Accelerated |
ASO therapy |
| A53T mutation |
Accelerated |
Aggregation inhibitor |
| GBA mutation |
Enhanced vulnerability |
Enzyme enhancement |
| LRRK2 G2019S |
Enhanced exosome release |
LRRK2 inhibitor |
| Age |
Declining clearance |
General proteostasis boost |
Skin biopsy represents a minimally invasive approach to detect pathological alpha-synuclein[@wang2026]:
| Parameter |
Specification |
| Biopsy Sites |
Posterior cervical, anterolateral thigh |
| Punch Size |
3-4mm diameter |
| Processing |
Fibroblast culture + RT-QuIC |
| Turnaround |
2-4 weeks |
| Sensitivity |
85-92% (PD) |
| Specificity |
90-96% |
- Differential diagnosis: Synucleinopathy vs. tauopathy
- Patient stratification: For clinical trials
- Longitudinal monitoring: Treatment response
- Alternative to LP: When lumbar puncture contraindicated
###血浆 SAA
Blood-based testing remains technically challenging due to:
- Low concentration of pathological species
- Presence of interfering proteins
- High background of normal alpha-synuclein
Recent advances have improved blood SAA sensitivity to 70-80%[@okuzumi2025], making it suitable for screening rather than definitive diagnosis.
| Tissue |
Detection Rate |
Utility |
| Submandibular gland |
70-85% |
Research |
| Colonic mucosa |
60-75% |
Research |
| Olfactory mucosa |
75-85% |
Research |
First-generation alpha-synuclein PET ligands are in clinical development[@kantarci2024]:
- Low density: Lewy bodies are smaller than amyloid plaques
- Background: Normal α-syn in neurons creates signal
- Selectivity: Distinguishing pathological from normal α-syn
- Blood-brain barrier: Ligand penetration
- First-in-human PET ligand results
- Validation in post-mortem tissue
- Correlation with SAA and CSF biomarkers
- Longitudinal changes with disease progression
Strategies to halt alpha-synuclein spreading include[@brundin2024]:
- Anle138b: Oligomer modulator - Phase 1/2
- SynuClean-D: Prevents α-syn fibrillation
- EPI-589: Redox-active molecule
- Prasinezumab (RO7046015): Phase 2 showed reduced progression
- Cinpanemab (BIIB054): Phase 2 subgroup analysis
- PD01A (Affiris): Active immunization
- ASOs: Targeting SNCA expression
- CRISPR-based: Gene editing for SNCA, LRRK2
SAA enables biomarker-driven patient selection:
- Enrichment: Selecting SAA-positive patients improves trial power
- Stratification: Kinetic parameters may predict progression
- Monitoring: Treatment response assessment
Expected presentations:
- SAA Clinical Implementation — Laboratory standardization and quality control
- Propagation Mechanisms Novel Insights — New cellular uptake pathways
- PET Imaging First Results — Alpha-synuclein ligand clinical data
- Peripheral Biomarker Advances — Skin biopsy validation studies
- Kinetic Prognostication — SAA kinetics predict progression
- Strain-Specific Therapy — Personalized approaches
MDS 2026 will feature dedicated sessions covering:
- Alpha-Synuclein SAA: From Research to Clinic — Clinical implementation pathways
- Propagation Mechanisms: New Therapeutic Targets — Cell-to-cell transmission
- Peripheral Biomarkers: Skin, Blood, and Beyond — Minimally invasive diagnostics
- Alpha-Synuclein PET Imaging — First human imaging results
- Prognostic Biomarkers: Kinetics Predict Progression — Disease progression modeling
- Disease-Modifying Therapies: Targeting Propagation — Therapeutic strategies
- Pezzullo AM, et al. Alpha-synuclein seed amplification assays in Parkinson's disease (2024)
- Orrú CD, et al. Diagnostic and prognostic value of αSyn SAA kinetic measures (2025)
- Siddiqi MK, et al. CSF alpha-synuclein RT-QuIC predicts disease progression in PD (2024)
- Iranzo A, et al. Longitudinal alpha-synuclein seeding in prodromal PD (2025)
- Wang Z, et al. Skin biopsy for alpha-synuclein seed amplification: A multicenter validation (2026)
- Brundin P, et al. Alpha-synuclein propagation in PD - therapeutic implications (2024)
- Valera E, et al. Alpha-synuclein prion-like behavior in PD (2023)
- Giguère NJ, et al. Cell-type-specific vulnerability to alpha-synuclein propagation (2024)
- Kantarci JT, et al. Alpha-synuclein PET imaging in PD - first-in-human results (2024)
- Bjornstad A, et al. CSF alpha-synuclein aggregation assay in prodromal PD (2024)